Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 2

1(25.0%)

Phase 4

1(25.0%)

4Total

N/A(2)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07401199Not Yet Recruiting

Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)

Role: collaborator

NCT07375979Not Yet Recruiting

A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study

Role: collaborator

NCT07153744Phase 4Not Yet Recruiting

Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction

Role: collaborator

NCT07003191Active Not Recruiting

Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes

Role: collaborator

NCT05955391Phase 2Active Not Recruiting

TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

Role: collaborator

NCT06201455Not ApplicableRecruiting

Evaluation of Phacogoniotomy in Medically-controlled POAG

Role: collaborator

NCT05683236Not ApplicableCompleted

The Clinical Effect of Palliative Treatment on Patients With Terminal Cancer

Role: lead

All 7 trials loaded